Active Filter(s):
Details:
The trial was designed to evaluate the proportion of patients who maintain their biochemical response to octreotide capsules and patient-reported outcomes in patients treated with octreotide capsules, compared to patients treated with leading injectable somatostatin analogs.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 05, 2021
Details:
Results from the ongoing OLE study show that the average IGF-1 levels of all patients treated with MYCAPSSA who completed the DPC period in the CHIASMA OPTIMAL trial and continued into the OLE were maintained within normal limits at the end of the 48-week OLE period.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
MYCAPSSA, the first and only oral somatostatin analog, approved by the U.S. FDA on June 26, 2020 for the long-term maintenance treatment of patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Chiasma has obtained approval from the US Food and Drug Administration for MYCAPSSA® (octreotide) capsules. MYCAPSSA is the first and only oral somatostatin analog (SSA) approved by the FDA.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
Chiasma intends to use the net proceeds from the offering primarily for advancing the ongoing commercialization of MYCAPSSA® in the United States for the treatment of acromegaly and for other pipeline activities.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Mycapssa
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 01, 2020